Stille AB

Stockholm Stock Exchange STIL.ST

Stille AB Price to Sales Ratio (P/S) on January 14, 2025: 5.89

Stille AB Price to Sales Ratio (P/S) is 5.89 on January 14, 2025, a 32.79% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Stille AB 52-week high Price to Sales Ratio (P/S) is 7.03 on July 22, 2024, which is 19.37% above the current Price to Sales Ratio (P/S).
Stille AB 52-week low Price to Sales Ratio (P/S) is 4.23 on February 06, 2024, which is -28.18% below the current Price to Sales Ratio (P/S).
Stille AB average Price to Sales Ratio (P/S) for the last 52 weeks is 5.75.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: STIL.ST

Stille AB

CEO	Mr. Torbjorn Skold
IPO Date	Nov. 29, 2005
Location	Sweden
Headquarters	Ekbacken 11
Employees	151
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.

Key trends

Past 5 years